For the Record

You have full text access to this OnlineOpen article

DNA sequence selectivity of human topoisomerase I-mediated DNA cleavage induced by camptothecin

  1. Chandanamali Punchihewa1,
  2. Megan Carver1,
  3. Danzhou Yang1,2,3,*

Article first published online: 16 APR 2009

DOI: 10.1002/pro.138

Issue

Protein Science

Protein Science

Volume 18, Issue 6, pages 1326–1331, June 2009

Additional Information

How to Cite

Punchihewa, C., Carver, M. and Yang, D. (2009), DNA sequence selectivity of human topoisomerase I-mediated DNA cleavage induced by camptothecin. Protein Science, 18: 1326–1331. doi: 10.1002/pro.138

Author Information

  1. 1

    College of Pharmacy, The University of Arizona, Tucson, Arizona 85721

  2. 2

    Arizona Cancer Center, Tucson, Arizona 85724

  3. 3

    BIO5 Institute, The University of Arizona, Tucson, Arizona 85721

*College of Pharmacy, The University of Arizona, 1703 E. Mabel St, Tucson, AZ 85721

Publication History

  1. Issue published online: 26 MAY 2009
  2. Article first published online: 16 APR 2009
  3. Accepted manuscript online: 16 APR 2009 12:00AM EST
  4. Manuscript Accepted: 8 APR 2009
  5. Manuscript Revised: 23 MAR 2009
  6. Manuscript Received: 23 JAN 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (239K)

References

  • 1
    Hsiang YH, Hertzberg R, Hecht S, Liu LF ( 1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873–14878.
  • 2
    Hsiang YH, Liu LF ( 1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48: 1722–1726.
  • 3
    Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB,Jr, Stewart L ( 2002) The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci USA 99: 15387–15392.
  • 4
    Rapisarda A, Uranchimeg B, Scudiero DA, Selby M, Sausville EA, Shoemaker RH, Melillo G ( 2002) Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62: 4316–4324.
  • 5
    Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G ( 2004) Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 64: 1475–1482.
  • 6
    Been MD, Burgess RR, Champoux JJ ( 1984) DNA strand breakage by wheat germ type 1 topoisomerase. Biochim Biophys Acta 782: 304–312.
  • 7
    Kjeldsen E, Mollerup S, Thomsen B, Bonven BJ, Bolund L, Westergaard O ( 1988) Sequence-dependent effect of camptothecin on human topoisomerase I DNA cleavage. J Mol Biol 202: 333–342.
  • 8
    Porter SE, Champoux JJ ( 1989) Mapping in vivo topoisomerase I sites on simian virus 40 DNA: asymmetric distribution of sites on replicating molecules. Mol Cell Biol 9: 541–550.
  • 9
    Jaxel C, Capranico G, Kerrigan D, Kohn KW, Pommier Y ( 1991) Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem 266: 20418–20423.
  • 10
    Tanizawa A, Kohn KW, Pommier Y ( 1993) Induction of cleavage in topoisomerase I c-DNA by topoisomerase I enzymes from calf thymus and wheat germ in the presence and absence of camptothecin. Nucleic Acids Res 21: 5157–5166.
  • 11
    Tanizawa A, Kohn KW, Kohlhagen G, Leteurtre F, Pommier Y ( 1995) Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry 34: 7200–7206.
  • 12
    Jaxel C, Kohn KW, Pommier Y ( 1988) Topoisomerase I interaction with SV40 DNA in the presence and absence of camptothecin. Nucleic Acids Res 16: 11157–11170.
  • 13
    Porter SE, Champoux JJ ( 1989) The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucleic Acids Res 17: 8521–8532.
  • 14
    Bonven BJ, Gocke E, Westergaard O ( 1985) A high affinity topoisomerase I binding sequence is clustered at DNAase I hypersensitive sites in Tetrahymena R-chromatin. Cell 41: 541–551.
  • 15
    Valenti M, Nieves-Neira W, Kohlhagen G, Kohn KW, Wall ME, Wani MC, Pommier Y ( 1997) Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells. Mol Pharmacol 52: 82–87.
  • 16
    Bailly C ( 2001) DNA relaxation and cleavage assays to study topoisomerase I inhibitors. Methods Enzymol 340: 610–623.
  • 17
    Pondarre C, Strumberg D, Fujimori A, Torres-Leon R, Pommier Y ( 1997) In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells. Nucleic Acids Res 25: 4111–4116.
  • 18
    Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WG Crystal ( 1998) Structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 279: 1504–1513.
  • 19
    Stewart L, Redinbo MR, Qiu X, Hol WG, Champoux JJ ( 1998) A model for the mechanism of human topoisomerase I. Science 279: 1534–1541.
  • 20
    Redinbo MR, Champoux JJ, Hol WG ( 2000) Novel insights into catalytic mechanism from a crystal structure of human topoisomerase I in complex with DNA. Biochemistry 39: 6832–6840.
  • 21
    Interthal H, Quigley PM, Hol WG, Champoux JJ ( 2004) The role of lysine 532 in the catalytic mechanism of human topoisomerase I. J Biol Chem 279: 2984–2992.
  • 22
    Stewart L, Champoux JJ ( 1997) Purification of baculovirus-expressed human DNA topoisomerase I. Methods Mol Biol 94: 223–234.
View Full Article with Supporting Information (HTML) Get PDF (239K)